Table of Contents Author Guidelines Submit a Manuscript
Pain Research and Management
Volume 10, Suppl A, Pages 15A-22A
http://dx.doi.org/10.1155/2005/242516
Review

Pharmacokinetics of Cannabinoids

Iain J McGilveray

McGilveray Pharmacon Inc, and University of Ottawa, Ottawa, Ontario, Canada

Copyright © 2005 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [47 citations]

The following is the list of published articles that have cited the current article.

  • Mohini Ranganathan, and Deepak Cyril D’Souza, “The acute effects of cannabinoids on memory in humans: a review,” Psychopharmacology, vol. 188, no. 4, pp. 425–444, 2006. View at Publisher · View at Google Scholar
  • Robert S. Goodwin, Richard A. Gustafson, Allan Barnes, Wesenyalsh Nebro, Eric T. Moolchan, and Marilyn A. Huestis, “??9-Tetrahydrocannabinol, 11-Hydroxy-??9-Tetrahydrocannabinol and 11-Nor-9-Carboxy-??9-Tetrahydrocannabinol in Human Plasma After Controlled Oral Administration of Cannabinoids,” Therapeutic Drug Monitoring, vol. 28, no. 4, pp. 545–551, 2006. View at Publisher · View at Google Scholar
  • Eric Murillo-Rodríguez, Diana Millán-Aldaco, Marcela Palomero-Rivero, Raphael Mechoulam, and René Drucker-Colín, “ Cannabidiol, a constituent of Cannabis sativa , modulates sleep in rats ,” FEBS Letters, vol. 580, no. 18, pp. 4337–4345, 2006. View at Publisher · View at Google Scholar
  • Johannes G Ramaekers, Gerold Kauert, Eef L Theunissen, and Manfred R Moeller, “Up in Smoke: Comparability of THC Dosing across Performance Studies,” Neuropsychopharmacology, vol. 31, no. 12, pp. 2800–2801, 2006. View at Publisher · View at Google Scholar
  • Sabine Steffens, and François Mach, “ Towards a therapeutic use of selective CB 2 cannabinoid receptor ligands for atherosclerosis ,” Future Cardiology, vol. 2, no. 1, pp. 49–53, 2006. View at Publisher · View at Google Scholar
  • Laurence Bonhomme-Faivre, Amine Benyamina, Michel Reynaud, Robert Farinotti, and Chadi Abbara, “ Disposition of Δ 9 tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein ,” Addiction Biology, vol. 13, no. 3-4, pp. 295–300, 2008. View at Publisher · View at Google Scholar
  • Delphine Psychoyos, Basalingappa Hungund, Thomas Cooper, and Richard H. Finnell, “ A cannabinoid analogue of Δ 9 -tetrahydrocannabinol disrupts neural development in chick ,” Birth Defects Research Part B: Developmental and Reproductive Toxicology, vol. 83, no. 5, pp. 477–488, 2008. View at Publisher · View at Google Scholar
  • Amitava Dasgupta, and Amitava Dasgupta, “Workplace Drug Testing: SAMHSA and Non-SAMHSA Drugs,” Beating Drug Tests and Defending Positive Results, pp. 29–44, 2009. View at Publisher · View at Google Scholar
  • Dana Turcotte, Josée-Anne Le Dorze, Farid Esfahani, Emma Frost, Andrew Gomori, and Mike Namaka, “Examining the roles of cannabinoids in pain and other therapeutic indications: a review,” Expert Opinion on Pharmacotherapy, vol. 11, no. 1, pp. 17–31, 2009. View at Publisher · View at Google Scholar
  • Michael Namaka, Christine Leong, Amy Grossberndt, Meghann Klowak, Dana Turcotte, Farid Esfahani, Andrew Gomori, and Howard Intrater, “A Treatment Algorithm for Neuropathic Pain: An Update,” The Consultant Pharmacist, vol. 24, no. 12, pp. 885–902, 2009. View at Publisher · View at Google Scholar
  • Benjamin Becker, Daniel Wagner, Euphrosyne Gouzoulis-Mayfrank, Elmar Spuentrup, and Jörg Daumann, “The impact of early-onset cannabis use on functional brain correlates of working memory,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 6, pp. 837–845, 2010. View at Publisher · View at Google Scholar
  • Ka Wesnes, P Annas, Cj Edgar, C Deeprose, R Karlsten, A Philipp, J Kalliomäki, and M Segerdahl, “Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers,” Journal of Psychopharmacology, vol. 24, no. 11, pp. 1659–1669, 2010. View at Publisher · View at Google Scholar
  • Wendy M. Bosker, Kim P. C. Kuypers, Eef L. Theunissen, Anke Surinx, Roos J. Blankespoor, Gisela Skopp, Wayne K. Jeffery, H. Chip Walls, Cees J. Leeuwen, and Johannes G. Ramaekers, “Medicinal Δ9-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests,” Addiction, vol. 107, no. 10, pp. 1837–1844, 2012. View at Publisher · View at Google Scholar
  • Amitava Dasgupta, “An Introduction to Tests Performed in Toxicology Laboratories,” Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring, pp. 1–30, 2012. View at Publisher · View at Google Scholar
  • Pradip Datta, “Genetic Aspect of Marijuana Metabolism and Abuse,” Pharmacogenomics of Alcohol and Drugs of Abuse, pp. 155–164, 2012. View at Publisher · View at Google Scholar
  • Sanjiv Kumra, Paul Robinson, Rabindra Tambyraja, Daniel Jensen, Caroline Schimunek, Alaa Houri, Tiffany Reis, and Kelvin Lim, “Parietal Lobe Volume Deficits in Adolescents With Schizophrenia and Adolescents With Cannabis Use Disorders,” Journal of the American Academy of Child & Adolescent Psychiatry, vol. 51, no. 2, pp. 171–180, 2012. View at Publisher · View at Google Scholar
  • Gillinder Bedi, Ziva D. Cooper, and Margaret Haney, “Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers,” Addiction Biology, vol. 18, no. 5, pp. 872–881, 2012. View at Publisher · View at Google Scholar
  • Margaret Haney, Ziva D Cooper, Gillinder Bedi, Suzanne K Vosburg, Sandra D Comer, and Richard W Foltin, “Nabilone Decreases Marijuana Withdrawal and a Laboratory Measure of Marijuana Relapse,” Neuropsychopharmacology, vol. 38, no. 8, pp. 1557–1565, 2013. View at Publisher · View at Google Scholar
  • Kim Wolff, and Atholl Johnston, “Cannabis use: a perspective in relation to the proposed UK drug-driving legislation,” Drug Testing and Analysis, vol. 6, no. 1-2, pp. 143–154, 2013. View at Publisher · View at Google Scholar
  • Joel Schlatter, “Synthetic Cannabinoids,” vol. 43, pp. 291–311, 2014. View at Publisher · View at Google Scholar
  • Adam Bisaga, Maria A. Sullivan, Andrew Glass, Kaitlyn Mishlen, Martina Pavlicova, Margaret Haney, Wilfrid N. Raby, Frances R. Levin, Kenneth M. Carpenter, John J. Mariani, and Edward V. Nunes, “The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone,” Drug and Alcohol Dependence, vol. 154, pp. 38–45, 2015. View at Publisher · View at Google Scholar
  • Crystal J. Jicha, Michelle R. Lofwall, Paul A. Nuzzo, Shanna Babalonis, Samy Claude Elayi, and Sharon L. Walsh, “Safety of oral dronabinol during opioid withdrawal in humans,” Drug and Alcohol Dependence, vol. 157, pp. 179–183, 2015. View at Publisher · View at Google Scholar
  • Michael H. Andreae, George M. Carter, Naum Shaparin, Kathryn Suslov, Ronald J. Ellis, Mark A. Ware, Donald I. Abrams, Hannah Prasad, Barth Wilsey, Debbie Indyk, Matthew Johnson, and Henry S. Sacks, “Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data,” The Journal of Pain, vol. 16, no. 12, pp. 1221–1232, 2015. View at Publisher · View at Google Scholar
  • Francesca Indorato, Aldo Liberto, Caterina Ledda, Guido Romano, and Nunziata Barbera, “The therapeutic use of cannabinoids: Forensic aspects,” Forensic Science International, vol. 265, pp. 200–203, 2016. View at Publisher · View at Google Scholar
  • Richard C. Kevin, David J. Allsop, Nicholas Lintzeris, Adrian J. Dunlop, Jessica Booth, and Iain S. McGregor, “Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal,” Forensic Toxicology, 2016. View at Publisher · View at Google Scholar
  • Antonio Leo, Emilio Russo, and Maurizio Elia, “Cannabidiol and epilepsy: Rationale and therapeutic potential,” Pharmacological Research, vol. 107, pp. 85–92, 2016. View at Publisher · View at Google Scholar
  • Z. Malik, L. Bayman, J. Valestin, A. Rizvi-Toner, S. Hashmi, and R. Schey, “Dronabinol increases pain threshold in patients with functional chest pain: a pilot double-blind placebo-controlled trial,” Diseases of the Esophagus, 2016. View at Publisher · View at Google Scholar
  • A. Mozayani, and G. Branum, “Pharmacology of Legal and Illicit Drugs,” Encyclopedia of Forensic and Legal Medicine, pp. 660–666, 2016. View at Publisher · View at Google Scholar
  • Chee W. Chia, Olga D. Carlson, David D. Liu, Isabel González-Mariscal, Sara Santa-Cruz Calvo, and Josephine M. Egan, “Incretin secretion in humans is under the influence of cannabinoid receptors,” American Journal of Physiology-Endocrinology and Metabolism, vol. 313, no. 3, pp. E359–E366, 2017. View at Publisher · View at Google Scholar
  • R. Bellmann, and M. Joannidis, “Vergiftungen mit psychotropen Substanzen,” Medizinische Klinik - Intensivmedizin und Notfallmedizin, 2017. View at Publisher · View at Google Scholar
  • Melissa E. Badowski, “A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics,” Cancer Chemotherapy and Pharmacology, 2017. View at Publisher · View at Google Scholar
  • Kunakorn Atchaneeyasakul, Luis F. Torres, and Amer M. Malik, “Large Amount of Cannabis Ingestion Resulting in Spontaneous Intracerebral Hemorrhage: A Case Report,” Journal of Stroke and Cerebrovascular Diseases, 2017. View at Publisher · View at Google Scholar
  • Carina Hasenoehrl, Martin Storr, and Rudolf Schicho, “Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?,” Expert Review of Gastroenterology & Hepatology, vol. 11, no. 4, pp. 329–337, 2017. View at Publisher · View at Google Scholar
  • Guido van Amerongen, Kawita Kanhai, Anne Catrien Baakman, Jules Heuberger, Erica Klaassen, Tim L. Beumer, Rob L.M. Strijers, Joep Killestein, Joop van Gerven, Adam Cohen, and Geert Jan Groeneveld, “Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-Tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis,” Clinical Therapeutics, 2017. View at Publisher · View at Google Scholar
  • Kaeli Zimmermann, Shuxia Yao, Marcel Heinz, Feng Zhou, Wolfgang Dau, Markus Banger, Bernd Weber, René Hurlemann, and Benjamin Becker, “Altered orbitofrontal activity and dorsal striatal connectivity during emotion processing in dependent marijuana users after 28 days of abstinence,” Psychopharmacology, 2017. View at Publisher · View at Google Scholar
  • Nir Friedman, Jessica Gantz, and Yaron Finkelstein, “An (Un)Fortune Cookie,” Pediatric Emergency Care, vol. 33, no. 12, pp. 811–814, 2017. View at Publisher · View at Google Scholar
  • Jacob Atsmon, Irina Cherniakov, Dvora Izgelov, Amnon Hoffman, Abraham J. Domb, Lisa Deutsch, Frederic Deutsch, Daphna Heffetz, and Hagit Sacks, “PTL401, a New Formulation Based on Pro-nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers,” Journal of Pharmaceutical Sciences, 2017. View at Publisher · View at Google Scholar
  • Jacob Atsmon, Daphna Heffetz, Lisa Deutsch, Frederic Deutsch, and Hagit Sacks, “Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology,” Clinical Pharmacology in Drug Development, 2017. View at Publisher · View at Google Scholar
  • Carola Rong, Nicole E. Carmona, Yena L. Lee, Renee-Marie Ragguett, Zihang Pan, Joshua D. Rosenblat, Mehala Subramaniapillai, Margarita Shekotikhina, Fahad Almatham, Asem Alageel, Rodrigo Mansur, Roger C. Ho, and Roger S. McIntyre, “ Drug-drug interactions as a result of co-administering Δ 9 -THC and CBD with other psychotropic agents ,” Expert Opinion on Drug Safety, pp. 1–4, 2017. View at Publisher · View at Google Scholar
  • R.E Balter, and M. Haney, “The Synthetic Analog of Δ9-Tetrahydrocannabinol (THC): Nabilone. Pharmacology and Clinical Application,” Handbook of Cannabis and Related Pathologies, pp. 821–827, 2017. View at Publisher · View at Google Scholar
  • Ana Lucić Vrdoljak, Nino Fuchs, Anja Mikolić, Suzana Žunec, Irena Brčić Karačonji, Andreja Jurič, Ljerka Prester, Vedran Micek, Marijana Neuberg, Samir Čanović, Gordan Mršić, and Nevenka Kopjar, “Irinotecan and Δ9-Tetrahydrocannabinol Interactions in Rat Liver: A Preliminary Evaluation Using Biochemical and Genotoxicity Markers,” Molecules, vol. 23, no. 6, pp. 1332, 2018. View at Publisher · View at Google Scholar
  • Caitlin R. M. Oyagawa, Sara M. de la Harpe, Yurii Saroz, Michelle Glass, Andrea J. Vernall, and Natasha Lillia Grimsey, “Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines,” Frontiers in Pharmacology, vol. 9, 2018. View at Publisher · View at Google Scholar
  • Yiqi Ruben Luo, Cassandra Yun, and Kara L Lynch, “Quantitation of Cannabinoids in Breath Samples Using a Novel Derivatization LC–MS/MS Assay with Ultra-High Sensitivity,” Journal of Analytical Toxicology, 2019. View at Publisher · View at Google Scholar
  • Erik L. Hodges, and Nicole M. Ashpole, “Aging Circadian Rhythms and Cannabinoids,” Neurobiology of Aging, 2019. View at Publisher · View at Google Scholar
  • Isaac P Marangoni, and Alejandro G Marangoni, “Cannabis Edibles: dosing, encapsulation and stability considerations,” Current Opinion in Food Science, 2019. View at Publisher · View at Google Scholar
  • Kaeli Zimmermann, Keith M. Kendrick, Dirk Scheele, Wolfgang Dau, Markus Banger, Wolfgang Maier, Bernd Weber, Yina Ma, René Hurlemann, and Benjamin Becker, “Altered striatal reward processing in abstinent dependent cannabis users: Social context matters,” European Neuropsychopharmacology, 2019. View at Publisher · View at Google Scholar
  • Matthew D. Krasowski, and Tai C. Kwong, “Analytical True Positive Drug Tests Due to Use of Prescription and Nonprescription Medications,” Critical Issues in Alcohol and Drugs of Abuse Testing, pp. 441–448, 2019. View at Publisher · View at Google Scholar